Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Ablation Catheters Market Size
Global ablation catheters market size was valued at USD 4.8 billion in 2024 and is projected to exhibit 13.6% CAGR from 2025-2034. The rising number of atrial fibrillation (AFib) and arrhythmia cases worldwide is fuelling the demand for ablation catheters.
To get key market trends
For example, the Centers for Disease Control and Prevention (CDC) indicates that AFib occurs in approximately 2% of individuals under the age of 65 and 9% of individuals aged 65 years and above in the U.S. This widespread prevalence has led to catheter ablation as a first-line treatment due to its low invasive procedure and high success rates in the long term, reflecting the continued need for ablation procedures.
Ablation Catheters Market Report Attributes
Report Attribute
Details
Base Year:
2024
Ablation Catheters Market size in 2024:
USD 4.8 Billion
Forecast Period:
2025 – 2034
Forecast Period 2023 - 2032 CAGR:
13.6
2023 Value Projection:
USD 17.2 Billion
Historical Data for:
2021 – 2024
No of Pages:
120
Tables, Charts & Figures:
126
Segments Covered:
Product Type, Technology, End Use, and Region
Growth Drivers:
Rising prevalence of atrial fibrillation and other cardiac arrhythmias
Technological advancements in ablation catheter design
Growing preference for minimally invasive procedures
Favorable reimbursement policies
Pitfalls Challenges:
High cost of ablation catheter procedures and equipment
Risk of complications such as cardiac perforation or thromboembolism
What are the growth opportunities in this market?
Emerging technology in catheter tip design, contact force technology, and emerging energy modalities like cryoablation and pulsed field ablation is enhancing procedure precision and safety. A number of new ablation systems have received U.S. Food and Drug Administration (FDA) approval in recent years, an indicator of the accelerated evolution of technology in this field. For example, Abbott Laboratories in May of 2023 reported that the U.S FDA had approved its Sensor Enabled TactiFlex Ablation Catheter, the first ablation catheter in the world to feature a flexible tip and contact force technology.
Moreover, as per the National Institutes of Health (NIH), long-term success rates for catheter ablation vary between 50% and 80% with increasing rates due to technological advancements, paralleling the increasing dependability of such procedures. These advances in technology are expanding clinical uses, boosting physician confidence, and driving increased utilization of ablation therapies across a range of healthcare settings.
Ablation catheters are advanced medical devices used in less invasive therapies for treatment of abnormal heart rhythm, or cardiac arrhythmia. Ablation catheters apply energy, radiofrequency, cryothermal, or pulsed electric fields to targeted heart tissue to destroy small areas of tissue that generate irregular electrical activity.
Ablation Catheters Market Trends
Pulsed Field Ablation (PFA) is revolutionizing cardiac ablation with its nonthermal electroporation mechanism of cardiac tissue ablation. The technology provides increased accuracy and reduces damage to neighboring tissues.
For example, according to Express Healthcare, PFA uptake is poised to hit 80% of electrophysiology ablation procedures by 2030, representing a paradigm shift in ablation procedures.
The market for ablation catheters continues to be dynamic with the introduction of innovation in catheter design, including increased manoeuvrability, contact force sensing, and compatibility with high-resolution 3D mapping technology. They improve procedural safety and accuracy, which leads to better patient outcomes as well as additional treatment options for the majority of arrhythmias.
In addition, cryoablation devices that uses extreme cold for cardiac tissue ablation shows growing adoption, particularly for AFib treatment.
The market is facing stronger competition with additional competitors, such as Boston Scientific's POLARx system, driving technological developments and increased utilization of cryoablation treatment.
Trump Administration Tariffs
The tariffs imposed by the Trump administration are expected to cause significant disruptions in the global supply chain, majorly affecting U.S.-based ablation catheter manufacturers that are dependent on outsourced components from providers in China and Europe.
Additionally, this can result in delayed procurement of critical components such as catheter shaft, ablation tip, irrigation system, and thermistors, resulting in possible bottlenecks and high overall manufacturing costs.
Various healthcare providers may have to pay higher prices for ablation catheters because of the increasing manufacturing costs. This can impact small-scale healthcare providers that lack the financial capacity to invest such huge amount.
Companies can adapt to the supply chain disruptions and cost hikes through cost optimization and supplier diversification. Moreover, manufacturers in China can strengthen their presence in the Asia and Africa regions having significant untapped potential for ablation catheters.
Ablation Catheters Market Analysis
Learn more about the key segments shaping this market
Based on product type, the market is bifurcated into multielectrode ablation catheters and single point ablation catheters. The multielectrode ablation catheters segment dominated the market with the largest revenue share of 61.3% in 2024.
The rising incidence of AFib worldwide has resulted in a rising demand for ablation catheters with both mapping and therapeutic capabilities.
For example, as per the Health Rhythm Society, around 40 million people globally were impacted by AFib in 2023.
Further, multielectrode ablation catheters provide simultaneous energy delivery in multiple locations with a shorter procedural time than from single-electrode systems.
This efficiency is advantageous to high-volume electrophysiology laboratories and challenging arrhythmia patients by reducing anesthesia time, enhancing workflow, enhancing patient throughput, lowering costs, and enhancing clinical outcome.
Based on technology, the ablation catheters market is segmented into radiofrequency (RF) ablation, cryoablation, and pulse field ablation. The radiofrequency (RF) ablation segment dominated the market with the largest revenue of USD 2.5 billion in 2024.
Radiofrequency ablation is a gold standard cardiac rhythm management device due to its demonstrated safety profile and repeatable clinical results.
The ability of the technique to produce accurate, permanent lesions has resulted in its widespread use across all healthcare institutions. The large body of clinical evidence for RF ablation catheters has made them the electrophysiologists' tool of choice worldwide.
Also, the integration of new features into RF ablation catheters such as contact force sensing, irrigated tips, and temperature-controlled energy delivery has enhanced procedural safety and efficacy. These technological advances improve lesion creation, reduce complications, and enhance procedural success.
Learn more about the key segments shaping this market
Based on end use, the ablation catheters market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a share of 62.2% in 2024.
Hospitals are seeing a rise in cardiac ablation procedures as the global incidence of AFib and other arrhythmias are increasing. With more patients receiving referrals for interventional procedure, hospitals have become the main arrhythmia management centers. Such a trend leads to higher use of ablation catheters, especially among cardiology units that conduct minimally invasive therapies.
Hospitals are expanding the size of their electrophysiology (EP) labs to accommodate the rising demand for diagnostic and therapeutic procedures for heart rhythm disorders.
Special ablation catheter systems are required for such facilities to provide successful treatment. Focus on the opening of well-facilitated cardiac care centers across these hospitals has led to a demand for high-performance ablation catheters, further contributing to the segment’s growth.
Looking for region specific data?
North America: The U.S. ablation catheters market is projected to grow significantly from USD 2 billion in 2024 to USD 6.9 billion by 2034.
The U.S. is experiencing an increasing incidence of cardiovascular conditions, including AFib and arrhythmias. The CDC states that about 12.1 million individuals in the U.S. will have AFib by 2030. This can be attributed to an aging population, sedentary lifestyle, and rising levels of hypertension and diabetes.
The increasing patient pool has generated tremendous demand for catheter-based ablation procedures, which has promoted rising adoption of ablation catheters in American healthcare centers, and hence, early intervention is critical to deal with cardiovascular conditions.
Furthermore, reimbursement policies and insurance coverage of the U.S. healthcare system for treatments of arrhythmia and catheter ablation procedures enhance market growth.
Europe: The ablation catheters market in UK is expected to experience significant and promising growth from 2025 to 2034.
The UK reports an increasing prevalence of AFib, especially in its aging population. According to the National Institutes of Health (NIH), in 2021, approximately 1.5 million people in the UK were living with AFib.
Since AFib remains a significant cause of stroke and morbidity, the demand for catheter-based ablation treatments continues to grow. The Stroke Association reports that AFib increases the risk of stroke by five times, highlighting the critical need for effective treatment options.
This rise in arrhythmia cases drives the ablation catheter market in the UK as healthcare facilities implement minimally invasive treatment options. Hence, the aforementioned factors are driving market growth in the region.
Asia Pacific: Japan ablation catheters market is anticipated to witness lucrative growth between 2025 – 2034.
Japan's ageing population at a very fast rate has resulted in the rise in cardiovascular diseases, especially arrhythmias like AFib. For example, Statista reported that in 2023, people 65 years and above in Japan accounted for around 29.6 percent of the entire Japanese population.
The population shift has created a higher demand for ablation procedures, which is driving the demand for advanced medical technology in cardiovascular care.
The healthcare system of Japan portrays superb uptake of advances in medical technology. Healthcare facilities continuously invest in high-tech equipment for enhancing patient care. This further helps to drive the adoption of advanced ablation catheters, significantly facilitating the market growth in the country.
Middle East and Africa: The Saudi Arabia ablation catheters market is expected to experience significant and promising growth from 2025 to 2034.
Saudi Arabia also experiences increasing cardiovascular disease, particularly among its elderly population and those who experience lifestyle risk factors like obesity, diabetes, and hypertension.
National Institutes of Health (NIH) estimates cardiovascular diseases as the cause of about 45.7% of the fatalities in Saudi Arabia, and therefore there is mounting demand for ablation catheter procedures in the cardiac treatment facilities.
Investments by the Saudi government in healthcare as part of Vision 2030 involve the increase in hospitals and specialized cardiac facilities. This infrastructure for healthcare fosters the implementation of ablation catheters and other technologies as a response to the increasing demand for cardiac rhythm disorder treatment.
Ablation Catheters Market Share
The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced surgical tools for the growing patient population. Companies such as Johnson & Johnson, Abbott Laboratories, Medtronic, Boston Scientific, and Biotronik are some of the dominant competitors in the market accounting for a combined market share of approximately 75%. Competition in this area arises from continuous technological developments and the ability to offer customized solutions for various cardiac surgery applications. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer ablation catheters that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
Ablation Catheters Market Companies
Some of the eminent market participants operating in the ablation catheters industry include:
Abbott Laboratories
AngioDynamics
AtriCure
Biotronik
Boston Scientific
CardioFocus
CathRx
Imricor Medical Systems
Japan Lifeline
Johnson & Johnson
Lepu Medical
Medtronic
MicroPort
Osypka
Stryker
Johnson & Johnson's Biosense Webster division is one the key player in the market that offers the THERMOCOOL SMARTTOUCH catheter, which has real-time contact force measurement capabilities. The technology ensures maximum tissue contact and minimized complications. Company-provides CARTO 3D mapping, which enable accurate visualization of cardiac anatomy, allowing electrophysiologists to make complex ablations, such as for AFib, more accurately.
Abbott's TactiFlex Ablation Catheter combines contact-force and flexible tip design to reinforce lesion durability during AFib procedures. Abbott's Freezor line is one of the key product series in the market for cryoablation, offering successful pulmonary vein isolation for patients with AFib. Abbott's EnSite X EP System offers high-resolution 3D mapping and can be combined with ablation catheters to improve procedural accuracy.
Medtronic's Arctic Front Cryoablation System demonstrates wide clinical experience in the treatment of AFib with successful pulmonary vein isolation and lower procedure times and complications than with radiofrequency ablation. Medtronic's PulseSelect Pulsed-Field Ablation system, FDA-approved in 2023, is thermal-free, selective ablation with reduced risk of esophageal and phrenic nerve injury.
Ablation Catheters Industry News:
In October 2024, Boston Scientific announced that it has received FDA clearance for its ablation catheter that is equipped with navigation capabilities to be used for the treatment of paroxysmal AFib, along with 510(k) clearance for fresh imaging software for its pulsed field ablation system. The clearance would serve to strengthen the company's product line and thus enable it to provide more accurate and effective treatment solutions, thus expanding its position.
In October 2024, Medtronic plc announced FDA approval for the Affera Mapping and Ablation System with Sphere-9 Catheter, a blended high-density mapping and pulsed field and radiofrequency ablation catheter for the treatment of persistent AFib and cavotricuspid isthmus-dependent atrial flutter. The approval was anticipated to strengthen Medtronic's portfolio, providing sophisticated solutions for arrhythmia therapy and solidifying its position in the market.
In May 2023, Abbott Laboratories reported that the U.S. FDA had approved Abbott's TactiFlex Ablation Catheter, which is the first ablation catheter with a flexible tip and contact force technology in the world. The clearance was expected to further strengthen Abbott's leadership position in the electrophysiology marketplace by offering a breakthrough solution that enhances accuracy and patient outcomes for ablation procedures.
In November 2021, Medtronic plc, a worldwide leader in healthcare technology, introduced the Arctic Front Cardiac Cryoablation Catheter System, the first and sole CDSCO-approved cryoballoon catheter on the market to treat AFib in India. Launch was poised to enable Medtronic to grow its presence in India's market while providing an innovative and clinically validated treatment for AFib.
The ablation catheters market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:
to Buy Section of this Report
By Product Type
Multielectrode ablation catheters
Single point ablation catheters
By Technology
Radiofrequency (RF) ablation
Cryoablation
Pulse field ablation
By End Use
Hospitals
Ambulatory surgical centers
Other end use
The above information is provided for the following regions and countries:
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Netherlands
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
What is the size of the U.S. ablation catheters market?+
The U.S. ablation catheters industry was valued at USD 2 billion in 2024 and is expected to reach USD 6.9 billion by 2034.
Who are some of the prominent players in the ablation catheters industry?+
Key players in the market include Abbott Laboratories, AngioDynamics, AtriCure, Biotronik, Boston Scientific, and CardioFocus.
How big is the ablation catheters market?+
The global ablation catheters industry was valued at USD 4.8 billion in 2024 and is projected to grow at a 13.6% CAGR from 2025 to 2034.
Which segment dominated the ablation catheters market in 2024?+
The hospitals segment led the market with a 62.2% share in 2024.